BARCELONA (MedPage Today) -- Ivabradine, a novel heart-rate reducing agent, increased the likelihood of death or heart attack when given to patients with activity-limiting angina who were already receiving standard background therapy for stable coronary artery disease. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment